<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01547104</url>
  </required_header>
  <id_info>
    <org_study_id>ikfe-Lina-002</org_study_id>
    <secondary_id>2012-000179-17</secondary_id>
    <nct_id>NCT01547104</nct_id>
  </id_info>
  <brief_title>Effect of Linagliptin in Comparison With Glimepiride as Add on to Metformin on Postprandial Beta Cell Function, Postprandial Metabolism and Oxidative Stress in Patients With Type 2 Diabetes Mellitus</brief_title>
  <official_title>Effect of Linagliptin in Comparison With Glimepiride as Add on to Metformin on Postprandial Beta Cell Function, Postprandial Metabolism and Oxidative Stress in Patients With Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Marcus Borchert</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ikfe-CRO GmbH</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>ikfe-CRO GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this mechanistic study is to investigate the effect of Linagliptin in comparison
      to Glimepiride as add on therapy on several parameters characterizing postprandial metabolism
      and oxidative stress in type 2 diabetic patients on stable control with metformin.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The goal of this mechanistic study is to investigate the effect of Linagliptin in comparison
      to Glimepiride as add on therapy on several parameters characterizing postprandial metabolism
      and oxidative stress in type 2 diabetic patients on stable control with metformin.

      This mechanistic phase IV study has a prospective, comparative, open, randomized, two arm and
      exploratory design. Overall 40 Patients will be randomized to two treatment arms both
      receiving Metformin at a maximally tolerated dose. In addition to that both treatment groups
      will receive either an individually titrated dose of Glimepiride or 5mg once daily of
      Linagliptin. Subsequent to a standardized meal, several parameters reflecting beta cell
      function, metabolism and oxidative stress will be evaluated.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2012</start_date>
  <completion_date type="Anticipated">October 2012</completion_date>
  <primary_completion_date type="Anticipated">October 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Postprandial increase in intact Proinsulin levels (Peak, AUC)</measure>
    <time_frame>30, 60, 90, 120, 150, 180, 210, 240, 270 300 mins post test meal procedure, 3 times within 12 weeks treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Postprandial Proinsulin/Insulin Ratio</measure>
    <time_frame>after 12 weeks treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Fasting intact Proinsulin levels</measure>
    <time_frame>after 12 weeks treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Fasting Proinsulin/Insulin Ratio</measure>
    <time_frame>after 12 weeks treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Fasting Blood Glucose</measure>
    <time_frame>after 12 weeks treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Postprandial Blood Glucose Excursions (Peak; AUC)</measure>
    <time_frame>30, 60, 90, 120, 150, 180, 210, 240, 270 300 mins post test meal procedure, 3 times within 12 weeks treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Fasting Lipids</measure>
    <time_frame>after 12 weeks treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Postprandial Lipids</measure>
    <time_frame>after 12 weeks treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Fasting Erythrocyte Flexibility</measure>
    <time_frame>after 12 weeks treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Postprandial Erythrocyte Flexibility</measure>
    <time_frame>after 12 weeks treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Fasting GLP-1 levels</measure>
    <time_frame>after 12 weeks treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Postprandial GLP-1 levels</measure>
    <time_frame>after 12 weeks treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Fasting cGMP</measure>
    <time_frame>after 12 weeks treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Postprandial cGMP</measure>
    <time_frame>after 12 weeks treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Fasting Calcitonin</measure>
    <time_frame>after 12 weeks treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Fasting PAI-1 levels</measure>
    <time_frame>after 12 weeks treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Postprandial PAI-1 levels</measure>
    <time_frame>after 12 weeks treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Fasting ADMA levels</measure>
    <time_frame>after 12 weeks treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Postprandial ADMA levels</measure>
    <time_frame>after 12 weeks treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Fasting Malonyldialdehyd</measure>
    <time_frame>after 12 weeks treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>fasting oxidatively modified nucleosides 8-oxodG and 8-oxoGuo</measure>
    <time_frame>after 12 weeks treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hypoglycemic events</measure>
    <time_frame>after 12 weeks treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body Weight</measure>
    <time_frame>after 12 weeks treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Diabetes Mellitus Type 2</condition>
  <arm_group>
    <arm_group_label>Glimepiride-ratiopharm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Glimepiride (1-4mg) as add on therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Trajenta</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Linagliptin 5 mg as add on therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Linagliptin</intervention_name>
    <description>Linagliptin dosed 5 mg as add on therapy to an existing metformin therapy</description>
    <arm_group_label>Trajenta</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glimepiride</intervention_name>
    <description>Glimepiride 1-4mg (individually dosed) as add on therapy to an existing metformin therapy</description>
    <arm_group_label>Glimepiride-ratiopharm</arm_group_label>
    <other_name>Glimepirid-ratiopharm</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Diabetes mellitus type 2

          2. HbA1c &gt; 6.5% - ≤ 8.5%

          3. HbA1c &gt; 7.0% - ≤ 8.5% for those patients with a significant cardiovascular history

          4. Treatment with metformin at a maximum tolerated dose

          5. Age 45 - 75 years (inclusively)

          6. Patient consents that his/her family physician/diabetologist will be informed of trial
             participation.

        Exclusion Criteria:

          1. Pretreatment with PPAR gamma agonists within the last three months

          2. History of type 1 diabetes

          3. Uncontrolled hypertension (systolic blood pressure &gt;160 mmHg and/or diastolic blood
             pressure &gt;90 mmHg)

          4. Acute infections

          5. Medical history of hypersensitivity to the study drugs or to drugs with similar
             chemical structures

          6. History of severe or multiple allergies

          7. Treatment with any other investigational drug within 3 months before trial entry.

          8. Progressive fatal disease

          9. History of drug or alcohol abuse in the past 2 years

         10. State after kidney transplantation

         11. Serum potassium &gt; 5.5 mmol/L

         12. Pregnancy or breast feeding

         13. Sexually active woman of childbearing age not practicing a highly effective method of
             birth control as defined as those which result in a low failure rate (i.e. less than
             1% per year) when used consistently and correctly such as implants, injectables,
             combined oral contraceptives, hormonal IUDs, sexual abstinence or vasectomized
             partner.

         14. Acute myocardial infarction, open heart surgery or cerebral event (stroke/TIA) within
             the previous 30 days

         15. Any elective surgery during study participation

         16. Have had more than one unexplained episode of severe hypoglycemia (defined as
             requiring assistance of another person due to disabling hypoglycemia) within 6 months
             prior to screening visit

         17. History of pancreatitis

         18. History of dehydration, pre-coma diabeticum or diabetic ketoacidosis

         19. Acute or scheduled investigation with iodine containing radiopaque material

         20. Uncontrolled unstable angina pectoris

         21. History of pericarditis, myocarditis, endocarditis

         22. Recent pulmonary embolism

         23. Hemodynamic relevant aortic stenosis

         24. Aortic aneurysm

         25. Regular use of NSAID's (no acute use of NSAID within 48 hours before V2,V4,V5)

         26. Lack of compliance or other similar reason that, according to investigator, precludes
             satisfactory participation in the study

         27. History of respiratory, gastrointestinal, hepatic (ALAT and/or ASAT &gt; 3 times the
             normal reference range), renal (Creatinine &gt; 1.1 mg/dl in women and &gt; 1.5 mg/dl in men
             ), neurological, psychiatric and/or hematological disease as judged by the
             investigator

         28. Lactose intolerance

         29. Intake of Coumarin or coumarin derived compounds such as phenprocoumon (Marcumar) or
             warfarin (Coumadin, Warfant)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Forst, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ikfe GmbH</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Thomas Forst, MD, PhD</last_name>
    <phone>+ 49 6131 57636</phone>
    <phone_ext>16</phone_ext>
    <email>ThomasF@ikfe.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Claudia Forkel</last_name>
    <phone>+ 49 6131 32790</phone>
    <phone_ext>32</phone_ext>
    <email>C.Forkel@ikfe-cro.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>ikfe GmbH</name>
      <address>
        <city>Mainz</city>
        <state>Rhineland-Palatinate</state>
        <zip>55116</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Forst, MD, PhD</last_name>
      <phone>+ 49 6131 57636</phone>
      <phone_ext>16</phone_ext>
      <email>ThomasF@ikfe.de</email>
    </contact>
    <contact_backup>
      <last_name>Daniela Sachsenheimer, MD</last_name>
      <phone>+ 49 6131 57636</phone>
      <phone_ext>46</phone_ext>
      <email>DanielaS@ikfe.de</email>
    </contact_backup>
    <investigator>
      <last_name>Daniela Sachsenheimer, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stephanie Helleberg, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stefan Diessel</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michael Mitry, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>April 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 21, 2012</study_first_submitted>
  <study_first_submitted_qc>March 2, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 7, 2012</study_first_posted>
  <last_update_submitted>April 10, 2012</last_update_submitted>
  <last_update_submitted_qc>April 10, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 11, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>ikfe-CRO GmbH</investigator_affiliation>
    <investigator_full_name>Marcus Borchert</investigator_full_name>
    <investigator_title>Prof. Dr. Thomas Forst</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glimepiride</mesh_term>
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Linagliptin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

